Tris Pharma

Executive Summary

Tris Pharma is a privately held biopharmaceutical company specializing in central nervous system (CNS) disorders, including ADHD, pain, and addiction. Founded in 2000 and headquartered in Monmouth Junction, New Jersey, the company leverages its proprietary drug delivery technologies—such as LiquiXR® and AdvaDDS™—to develop differentiated, patient-friendly formulations. Its lead commercial products, Quillivant XR® and QuilliChew ER®, are established ADHD treatments that have generated steady revenue. Beyond ADHD, Tris is advancing a pipeline of abuse-deterrent and novel therapies for pain management and substance use disorders, aiming to address significant unmet needs in the CNS space. The company's robust intellectual property portfolio and proven ability to bring products to market position it as a notable player in the specialty pharmaceutical sector. Despite being private, Tris Pharma's commercial success and late-stage pipeline suggest significant potential for growth through label expansions, new product approvals, or strategic partnerships.

Upcoming Catalysts (preview)

• H2 2026FDA decision on abuse-deterrent opioid formulation60% success
• Q1 2027Phase 3 top-line results for novel ADHD liquid formulation70% success
• 2026Potential licensing or partnership deal for CNS pipeline asset50% success